Travere Therapeutics Inc (TVTX) is expecting 53.19% growth in the next quarter: What can investors do to maximize their returns?

Travere Therapeutics Inc (NASDAQ: TVTX) on Tuesday, plunged -0.11% from the previous trading day, before settling in for the closing price of $18.77. Within the past 52 weeks, TVTX’s price has moved between $5.12 and $20.33.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

During the last 5-year period, the sales growth of Healthcare Sector giant was 3.07%. The company achieved an average annual earnings per share of -162.28%. With a float of $85.72 million, this company’s outstanding shares have now reached $87.03 million.

Let’s determine the extent of company efficiency that accounts for 380 employees. In terms of profitability, gross margin is 84.29%, operating margin of -169.03%, and the pretax margin is -171.4%.

Travere Therapeutics Inc (TVTX) Insider Activity

Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Travere Therapeutics Inc is 1.52%, while institutional ownership is 97.31%. The most recent insider transaction that took place on Nov 25 ’24, was worth 221,258. In this transaction SVP, CHIEF ACCOUNTING OFFICER of this company sold 12,090 shares at a rate of $18.30, taking the stock ownership to the 54,927 shares. Before that another transaction happened on Nov 25 ’24, when Company’s Officer proposed sale 12,090 for $18.30, making the entire transaction worth $221,258.

Travere Therapeutics Inc (TVTX) Earnings and Forecasts

Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.3 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around -162.28% per share during the next fiscal year.

Travere Therapeutics Inc (NASDAQ: TVTX) Trading Performance Indicators

Travere Therapeutics Inc (TVTX) is currently performing well based on its current performance indicators. A quick ratio of 1.68 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.02.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.56, a number that is poised to hit -0.64 in the next quarter and is forecasted to reach -1.19 in one year’s time.

Technical Analysis of Travere Therapeutics Inc (TVTX)

Looking closely at Travere Therapeutics Inc (NASDAQ: TVTX), its last 5-days average volume was 0.99 million, which is a drop from its year-to-date volume of 1.39 million. As of the previous 9 days, the stock’s Stochastic %D was 50.55%. Additionally, its Average True Range was 0.87.

During the past 100 days, Travere Therapeutics Inc’s (TVTX) raw stochastic average was set at 87.26%, which indicates a significant increase from 57.82% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 32.05% in the past 14 days, which was lower than the 61.74% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $17.76, while its 200-day Moving Average is $10.80. However, in the short run, Travere Therapeutics Inc’s stock first resistance to watch stands at $19.10. Second resistance stands at $19.45. The third major resistance level sits at $19.70. If the price goes on to break the first support level at $18.50, it is likely to go to the next support level at $18.25. Should the price break the second support level, the third support level stands at $17.90.

Travere Therapeutics Inc (NASDAQ: TVTX) Key Stats

Market capitalization of the company is 1.63 billion based on 78,050K outstanding shares. Right now, sales total 145,240 K and income totals -111,400 K. The company made 62,900 K in profit during its latest quarter, and -54,810 K in sales during its previous quarter.